open access

Online first
Review paper
Published online: 2023-02-27
Get Citation

Cardiovascular disease in women: Do we need new diagnostic and therapeutic strategies?

Pilar Jiménez-Quevedo1, Concepción Alonso-Martin2, Raquel Campuzano Ruiz3, Gabriela Guzmán-Martinez456, Milagros Pedreira Perez7, Antonia Sambola78
DOI: 10.33963/KP.a2023.0051
·
Pubmed: 36871309
Affiliations
  1. Clinico San Carlos University Hospital, IdISSC, Madrid, Spain
  2. Arrhythmia Unit, Department of Cardiology. Hospital de la Santa Creu i Sant Pau, CIBERCV, Instituto de Recerca HSCSP-IIb Sant Pau, Universidad autónoma de Barcelona, Barcelona, Spain
  3. Cardiac Rehabilitation Unit, Department of Cardiology, Universitary Hospital Fundación Alcorcón, Madrid, Spain
  4. Department of Cardiology, La Paz University Hospital, IdiPaz, Madrid, Spain
  5. Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain
  6. Atrys Health, Madrid, Spain
  7. Cardio-oncology and Cardiovascular Disease in Women Unit, Department of Cardiology, Universitary Hospital Santiago de Compostela, Spain
  8. Department of Cardiology and Research Institute, University Hospital Vall d’Hebron, Universitat Autònoma, CIBER Cardiovascular Diseases (CIBER-CV), Barcelona, Spain

open access

Online first
Review article
Published online: 2023-02-27

Abstract

Cardiovascular disease (CVD) is the leading cause of death worldwide affecting both genders equally. However, in comparison to men, in women it often is underrecognized and undertreated in both the primary and secondary prevention settings. It is clear, that in the healthy population, there are profound differences both anatomically and biochemically between woman and men and this may impact how both groups present when they become ill. Therefore, there are some diseases that affect more frequently in women than in men such us myocardial ischemia or infarction without obstructive coronary disease, Tako-subo syndrome, some atrial arrhythmias or the appearance of heart failure with preserved ejection fraction. Therefore, the diagnostic and therapeutic strategies that have been established based largely on clinical studies with a predominant male population must be adapted before being applied to women. There is a paucity of data regarding cardiovascular disease in women. It is inadequate to only perform a subgroup analysis evaluating a specific treatment or invasive technique, when women constitute fifty percent of the population. In this regard, this may affect the time of clinical diagnosis and severity assessments of some valvulopathies. In this review, we will focus on the differences in the diagnosis, management, and outcomes of woman with the most frequent cardiovascular pathologies including coronary artery disease, arrythmias, heart failure and valvopathies. In addition, we will describe diseases that exclusively affect to women related with the pregnancy some of them are life treating. Although the lack of research in women plays a role in the poorer outcomes in women specially in ischemic heart disease the results of some techniques such as transcathether aortic valve implantation and transcatheter edge to edge therapy seem to have better outcome in women.

Abstract

Cardiovascular disease (CVD) is the leading cause of death worldwide affecting both genders equally. However, in comparison to men, in women it often is underrecognized and undertreated in both the primary and secondary prevention settings. It is clear, that in the healthy population, there are profound differences both anatomically and biochemically between woman and men and this may impact how both groups present when they become ill. Therefore, there are some diseases that affect more frequently in women than in men such us myocardial ischemia or infarction without obstructive coronary disease, Tako-subo syndrome, some atrial arrhythmias or the appearance of heart failure with preserved ejection fraction. Therefore, the diagnostic and therapeutic strategies that have been established based largely on clinical studies with a predominant male population must be adapted before being applied to women. There is a paucity of data regarding cardiovascular disease in women. It is inadequate to only perform a subgroup analysis evaluating a specific treatment or invasive technique, when women constitute fifty percent of the population. In this regard, this may affect the time of clinical diagnosis and severity assessments of some valvulopathies. In this review, we will focus on the differences in the diagnosis, management, and outcomes of woman with the most frequent cardiovascular pathologies including coronary artery disease, arrythmias, heart failure and valvopathies. In addition, we will describe diseases that exclusively affect to women related with the pregnancy some of them are life treating. Although the lack of research in women plays a role in the poorer outcomes in women specially in ischemic heart disease the results of some techniques such as transcathether aortic valve implantation and transcatheter edge to edge therapy seem to have better outcome in women.

Get Citation

Keywords

acute coronary syndrome, arrhythmia, cardiovascular disease, valvulopathy, woman

About this article
Title

Cardiovascular disease in women: Do we need new diagnostic and therapeutic strategies?

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Online first

Article type

Review paper

Published online

2023-02-27

Page views

56

Article views/downloads

29

DOI

10.33963/KP.a2023.0051

Pubmed

36871309

Keywords

acute coronary syndrome
arrhythmia
cardiovascular disease
valvulopathy
woman

Authors

Pilar Jiménez-Quevedo
Concepción Alonso-Martin
Raquel Campuzano Ruiz
Gabriela Guzmán-Martinez
Milagros Pedreira Perez
Antonia Sambola

References (98)
  1. Global Burden of Disease Study 2019 (GBD 2019) results. Seattle, WA, US: Institute for Health Metrics and Evaluation, 2020. Available online: http://ghdx.healthdata.org/ gbd-results-tool. Accessed: April 23, 2021.
  2. Woodward M. Cardiovascular disease and the female disadvantage. Int J Environ Res Public Health. 2019; 16(7).
  3. Osibogun O, Ogunmoroti O, Kolade OB, et al. A systematic review and meta-analysis of the association between polycystic ovary syndrome and coronary artery calcification. J Womens Health (Larchmt). 2022; 31(6): 762–771.
  4. Castro A, Goya M, Delgado J, et al. Follow-up recommendations for the “fourth trimester” in women with vascular and metabolic complications during pregnancy. Consensus Document of SEC, SEMERGEN, semFYC, and SEGO. RECardio Clinics. 2020; 55: 38–46.
  5. Boucheron P, Lailler G, Moutengou E, et al. Hypertensive disorders of pregnancy and onset of chronic hypertension in France: the nationwide CONCEPTION study. Eur Heart J. 2022; 43(35): 3352–3361.
  6. Diaz-Santana MV, O'Brien KM, Park YMM, et al. Persistence of risk for type 2 diabetes after gestational diabetes mellitus. Diabetes Care. 2022; 45(4): 864–870.
  7. Ukah UV, Auger N. Severe maternal morbidity and risk of cardiovascular disease: Recent advances. Kardiol Pol. 2022; 80(6): 638–643.
  8. Nappi RE, Chedraui P, Lambrinoudaki I, et al. Menopause: a cardiometabolic transition. Lancet Diabetes Endocrinol. 2022; 10(6): 442–456.
  9. Akyea RK, Kontopantelis E, Kai J, et al. Sex disparity in subsequent outcomes in survivors of coronary heart disease. Heart. 2022; 108(1): 37–45.
  10. Hyun K, Negrone A, Redfern J, et al. Gender difference in secondary prevention of cardiovascular disease and outcomes following the survival of acute coronary syndrome. Heart Lung Circ. 2021; 30(1): 121–127.
  11. Thakkar A, Agarwala A, Michos ED. Secondary prevention of cardiovascular disease in women: closing the gap. Eur Cardiol. 2021; 16: e41.
  12. Vynckier P, Ferrannini G, Rydén L, et al. Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V registry. Eur J Prev Cardiol. 2022; 29(2): 344–351.
  13. Colbert JD, Martin BJ, Haykowsky MJ, et al. Cardiac rehabilitation referral, attendance and mortality in women. Eur J Prev Cardiol. 2015; 22(8): 979–986.
  14. Ekblom Ö, Cider Å, Hambraeus K, et al. Physical inactivity and smoking after myocardial infarction as predictors for readmission and survival: results from the SWEDEHEART-registry. Clin Res Cardiol. 2019; 108(3): 324–332.
  15. Canto JG, Rogers WJ, Goldberg RJ, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA. 2012; 307(8): 813–822.
  16. McSweeney J, Rosenfeld A, Abel W, et al. Preventing and experiencing ischemic heart disease as a woman: state of the science. Circulation. 2016; 133(13): 1302–1331.
  17. Lichtman JH, Leifheit EC, Safdar B, et al. Variation in recovery: Role of gender on outcomes of young AMI patients (VIRGO) study design. Circ Cardiovasc Qual Outcomes. 2010; 3(6): 684–693.
  18. Gulati M, Levy D, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021; 144(22): e368–e454.
  19. Mosca L, Hammond G, Mochari-Greenberger H, et al. Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association national survey. Circulation. 2013; 127(11): 1254–63, e1.
  20. Fink N, Nikolsky E, Assali A, et al. Revascularization strategies and survival in patients with multivessel coronary artery disease. Ann Thorac Surg. 2019; 107(1): 106–111.
  21. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
  22. Mieres JH, Gulati M, Bairey Merz N, et al. Role of noninvasive testing in the clinical evaluation of women with suspected ischemic heart disease: a consensus statement from the American Heart Association. Circulation. 2014; 130(4): 350–379.
  23. Hoffmann U, Ferencik M, Udelson JE, et al. Prognostic Value of Noninvasive Cardiovascular Testing in Patients With Stable Chest Pain: Insights From the PROMISE Trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). Circulation. 2017; 135(24): 2320–2332.
  24. Schulman-Marcus J, Hartaigh BÓ, Gransar H, et al. Sex-Specific Associations Between Coronary Artery Plaque Extent and Risk of Major Adverse Cardiovascular Events: The CONFIRM Long-Term Registry. JACC Cardiovasc Imaging. 2016; 9(4): 364–372.
  25. Hemal K, Pagidipati NJ, Coles A, et al. Sex Differences in Demographics, Risk Factors, Presentation, and Noninvasive Testing in Stable Outpatients With Suspected Coronary Artery Disease: Insights From the PROMISE Trial. JACC Cardiovasc Imaging. 2016; 9(4): 337–346.
  26. Newby DE, Adamson PD, Berry C, et al. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction. N Engl J Med. 2018; 379(10): 924–933.
  27. Devries S, Wolfkiel C, Fusman B, et al. Influence of age and gender on the presence of coronary calcium detected by ultrafast computed tomography. J Am Coll Cardiol. 1995; 25(1): 76–82.
  28. Solola Nussbaum S, Henry S, Yong CM, et al. Sex-Specific Considerations in the Presentation, Diagnosis, and Management of Ischemic Heart Disease: JACC Focus Seminar 2/7. J Am Coll Cardiol. 2022; 79(14): 1398–1406.
  29. Bairey Merz CN, Pepine CJ, Walsh MN, et al. Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade. Circulation. 2017; 135(11): 1075–1092.
  30. Kenkre TS, Malhotra P, Johnson BD, et al. Ten-Year Mortality in the WISE Study (Women's Ischemia Syndrome Evaluation). Circ Cardiovasc Qual Outcomes. 2017; 10(12).
  31. Handberg EM, Merz CN, Cooper-Dehoff RM, et al. Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial. Am Heart J. 2021; 237: 90–103.
  32. Bhatt DL, Lopes RD, Harrington RA. Diagnosis and treatment of acute coronary syndromes: a review. JAMA. 2022; 327(7): 662–675.
  33. Arora S, Stouffer GA, Kucharska-Newton AM, et al. Twenty year trends and sex differences in young adults hospitalized with acute myocardial infarction. Circulation. 2019; 139(8): 1047–1056.
  34. Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017; 38(3): 143–153.
  35. Dreyer RP, Beltrame JF, Tavella R, et al. Evaluation of gender differences in Door-to-Balloon time in ST-elevation myocardial infarction. Heart Lung Circ. 2013; 22(10): 861–869.
  36. Sederholm Lawesson S, Isaksson RM, Ericsson M, et al. Gender disparities in first medical contact and delay in ST-elevation myocardial infarction: a prospective multicentre Swedish survey study. BMJ Open. 2018; 8(5): e020211.
  37. van Oosterhout REM, de Boer AR, Maas AH, et al. Sex differences in symptom presentation in acute coronary syndromes: a systematic review and meta-analysis. J Am Heart Assoc. 2020; 9(9): e014733.
  38. Sambola A, Elola FJ, Ferreiro JL, et al. Impact of sex differences and network systems on the in-hospital mortality of patients with ST-segment elevation acute myocardial infarction. Rev Esp Cardiol (Engl Ed). 2021; 74(11): 927–934.
  39. Gore MO, Seliger SL, Defilippi CR, et al. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol. 2014; 63(14): 1441–1448.
  40. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Russian Journal of Cardiology. 2021; 26(3): 4418.
  41. Gupta T, Kolte D, Khera S, et al. Contemporary sex-based differences by age in presenting characteristics, use of an early invasive strategy, and inhospital mortality in patients with non-ST-segment-elevation myocardial infarction in the united states. Circ Cardiovasc Interv. 2018; 11(1): e005735.
  42. Wenzl FA, Kraler S, Ambler G, et al. Sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multinational analysis with external cohort validation. Lancet. 2022; 400(10354): 744–756.
  43. LaPointe NM, Chen AY, Alexander KP, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005; 294(24): 3108–3116.
  44. Lau ES, Braunwald E, Murphy SA, et al. Potent P2Y Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017; 69(12): 1549–1559.
  45. Dagan M, Dinh DT, Stehli J, et al. Sex disparity in secondary prevention pharmacotherapy and clinical outcomes following acute coronary syndrome. Eur Heart J Qual Care Clin Outcomes. 2022; 8(4): 420–428.
  46. Chokshi NP, Iqbal SN, Berger RL, et al. Sex and race are associated with the absence of epicardial coronary artery obstructive disease at angiography in patients with acute coronary syndromes. Clin Cardiol. 2010; 33(8): 495–501.
  47. Smilowitz NR, Mahajan AM, Roe MT, et al. Mortality of Myocardial Infarction by Sex, Age, and Obstructive Coronary Artery Disease Status in the ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines). Circ Cardiovasc Qual Outcomes. 2017; 10(12): e003443.
  48. Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine--short version. Eur Heart J. 2015; 36(30): 1958–1966.
  49. Hoshida S, Watanabe T, Shinoda Y, et al. Sex-related differences in left ventricular diastolic function and arterial elastance during admission in patients with heart failure with preserved ejection fraction: The PURSUIT HFpEF study. Clin Cardiol. 2018; 41(12): 1529–1536.
  50. Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004; 109(4): 494–499.
  51. Sambola A, Elola FJ, Buera I, et al. Sex bias in admission to tertiary-care centres for acute myocardial infarction and cardiogenic shock. Eur J Clin Invest. 2021; 51(7): e13526.
  52. Gevaert SA, Halvorsen S, Sinnaeve PR, et al. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Clinical Consensus Statement of the Acute CardioVascular Care Association (ACVC) and the ESC council of Cardio-Oncology-part 2: acute heart failure, acute myocardial diseases, acute venous thromboembolic diseases, and acute arrhythmias. Eur Heart J Acute Cardiovasc Care. 2022; 11(11): 865–874.
  53. Lam CSP, Arnott C, Beale AL, et al. Sex differences in heart failure. Eur Heart J. 2019; 40(47): 3859–3868c.
  54. Galvao M, Kalman J, DeMarco T, et al. Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Card Fail. 2006; 12(2): 100–107.
  55. McDonagh T, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Revista Española de Cardiología (English Edition). 2022; 75(6): 523.
  56. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353(9146): 9–13.
  57. Flather MD, Shibata MC, Coats AJS, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26(3): 215–225.
  58. Tepper D, Gullestad L, Ueland T, et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353(9169): 2001–2007.
  59. Rouleau JL, Roecker EB, Tendera M, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002; 106(17): 2194–2199.
  60. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003; 362(9386): 777–781.
  61. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345(23): 1667–1675.
  62. Yusuf S, Pitt B, Davis CE, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325(5): 293–302.
  63. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364(1): 11–21.
  64. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10): 709–717.
  65. Packer M, Anker S, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Eng J Med. 2020; 383(15): 1413–1424.
  66. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022; 28(3): 568–574.
  67. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381: 1995–2008.
  68. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.
  69. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002; 347(18): 1403–1411.
  70. Adams K, Patterson J, Gattis W, et al. Relationship of Serum Digoxin Concentration to Mortality and Morbidity in Women in the Digitalis Investigation Group (DIG) Trial: A Retrospective Analysis. Journal of Cardiac Failure. 2004; 10(4): S23.
  71. Santema BT, Ouwerkerk W, Tromp J, et al. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet. 2019; 394(10205): 1254–1263.
  72. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016; 18(9): 1096–1105.
  73. Lyon AR, Bossone E, Schneider B, et al. Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016; 18(1): 8–27.
  74. Isorni MA, Aissaoui N, Angoulvant D, et al. Temporal trends in clinical characteristics and management according to sex in patients with cardiogenic shock after acute myocardial infarction: The FAST-MI programme. Arch Cardiovasc Dis. 2018; 111(10): 555–563.
  75. Vallabhajosyula S, Ya'Qoub L, Singh M, et al. Sex Disparities in the Management and Outcomes of Cardiogenic Shock Complicating Acute Myocardial Infarction in the Young. Circ Heart Fail. 2020; 13(10): e007154.
  76. Fengler K, Fuernau G, Desch S, et al. Gender differences in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial. Clin Res Cardiol. 2015; 104(1): 71–78.
  77. Linde C, Bongiorni MG, Birgersdotter-Green U, et al. Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. Europace. 2018; 20(10): 1565–1565ao.
  78. Liuba I, Jönsson A, Säfström K, et al. Gender-related differences in patients with atrioventricular nodal reentry tachycardia. Am J Cardiol. 2006; 97(3): 384–388.
  79. Carnlöf C, Iwarzon M, Jensen-Urstad M, et al. Women with PSVT are often misdiagnosed, referred later than men, and have more symptoms after ablation. Scand Cardiovasc J. 2017; 51(6): 299–307.
  80. Katritsis DG, Zografos T, Katritsis GD, et al. Catheter ablation vs. antiarrhythmic drug therapy in patients with symptomatic atrioventricular nodal re-entrant tachycardia: a randomized, controlled trial. Europace. 2017; 19(4): 602–606.
  81. Wilke T, Groth A, Mueller S, et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost. 2012; 107(6): 1053–1065.
  82. Lip GYH, Laroche C, Boriani G, et al. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace. 2015; 17(1): 24–31.
  83. Saeed S, Dweck MR, Chambers J. Sex differences in aortic stenosis: from pathophysiology to treatment. Expert Rev Cardiovasc Ther. 2020; 18(2): 65–76.
  84. Leon M, Smith C, Mack M, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. New England Journal of Medicine. 2010; 363(17): 1597–1607.
  85. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016; 374: 1609–1620.
  86. Mack M, Leon M, Thourani V, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Eng J Med. 2019; 380(18): 1695–1705.
  87. Laricchia A, Bellini B, Romano V, et al. Sex and Transcatheter Aortic Valve Implantation: Impact of Female Sex on Clinical Outcomes. Interv Cardiol. 2019; 14(3): 137–141.
  88. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. EuroIntervention. 2022; 17(14): e1126–e1196.
  89. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006; 368(9540): 1005–1011.
  90. Andell P, Li X, Martinsson A, et al. Epidemiology of valvular heart disease in a Swedish nationwide hospital-based register study. Heart. 2017; 103(21): 1696–1703.
  91. Avierinos JF, Inamo J, Grigioni F, et al. Sex differences in morphology and outcomes of mitral valve prolapse. Ann Intern Med. 2008; 149(11): 787–795.
  92. Elmariah S, Budoff MJ, Delaney JAC, et al. Risk factors associated with the incidence and progression of mitral annulus calcification: the multi-ethnic study of atherosclerosis. Am Heart J. 2013; 166(5): 904–912.
  93. Fleury MA, Clavel MA. Sex and race differences in the pathophysiology, diagnosis, treatment, and outcomes of valvular heart diseases. Can J Cardiol. 2021; 37(7): 980–991.
  94. Vassileva CM, McNeely C, Mishkel G, et al. Gender differences in long-term survival of Medicare beneficiaries undergoing mitral valve operations. Ann Thorac Surg. 2013; 96(4): 1367–1373.
  95. McNeely C, Vassileva C. Mitral Valve Surgery in Women: Another Target for Eradicating Sex Inequality. Circ Cardiovasc Qual Outcomes. 2016; 9(2 Suppl 1): S94–S96.
  96. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. ESC Scientific Document Group. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39(34): 3165–3241.
  97. Kosmidou I, Lindenfeld J, Abraham WT, et al. Sex-Specific Outcomes of Transcatheter Mitral-Valve Repair and Medical Therapy for Mitral Regurgitation in Heart Failure. JACC Heart Fail. 2021; 9(9): 674–683.
  98. Dietz MF, Prihadi EA, van der Bijl P, et al. Sex-Specific Differences in Etiology and Prognosis in Patients With Significant Tricuspid Regurgitation. Am J Cardiol. 2021; 147: 109–115.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl